– New data showcase safety profile of twice-yearly lenacapavir for PrEP with other medications and recruitment strategies for PURPOSE 5 –
– Five-year BICSTaR results offer insights into long-term treatment with Biktarvy®, helping inform the future of coordinated, person-centered HIV care –
– Latest results on novel long-acting combination regimens, including once-weekly and twice-yearly treatment options –
Read the full company press release here.
Source : Gilead Sciences, Inc.